Skip to content
BioSupply Trends Quarterly logo
  • About Us
  • About Us
Subscribe
  • News
    • Artificial Intelligence
    • Biosimilars
    • Clinical Trials
    • COVID
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Therapeutics
    • Vaccines
    • Washington Report
  • Industry Insight
    • Artificial Intelligence
    • Biosimilars
    • Chronic Illness
    • COVID
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
  • Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
  • Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
  • Issues
    • Current Issue
    • Past Issues
  • News
    • Artificial Intelligence
    • Biosimilars
    • Clinical Trials
    • COVID
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Therapeutics
    • Vaccines
    • Washington Report
  • Industry Insight
    • Artificial Intelligence
    • Biosimilars
    • Chronic Illness
    • COVID
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
  • Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
  • Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
  • Issues
    • Current Issue
    • Past Issues
  • Home
  • News
    • All News
    • Artificial Intelligence
    • Biosimilars
    • Clinical Trials
    • COVID
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Therapeutics
    • Vaccines
    • Washington Report
  • Industry Insight
    • All Industry Insight
    • Artificial Intelligence
    • Biosimilars
    • Chronic Illness
    • COVID
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
  • Operations & Management
    • All Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
  • Perspectives
    • All Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
  • Issues
    • Current Issue
    • Past Issues
  • Subscribe
  • About Us
  • Home
  • News
    • All News
    • Artificial Intelligence
    • Biosimilars
    • Clinical Trials
    • COVID
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Therapeutics
    • Vaccines
    • Washington Report
  • Industry Insight
    • All Industry Insight
    • Artificial Intelligence
    • Biosimilars
    • Chronic Illness
    • COVID
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
  • Operations & Management
    • All Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
  • Perspectives
    • All Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
  • Issues
    • Current Issue
    • Past Issues
  • Subscribe
  • About Us
BioSupply Trends Quarterly logo

Category: News

CMS Proposes Payment Cut for Physicians

CMS issued a proposed rule that announces and solicits public comments on proposed policy changes for Medicare payments on or after Jan. 1, 2025.

FDA Modernizes Informed Consent Guidance, Aligning with Common Rule Changes

FDA has published new draft guidance on informed consent that lines up with revisions to the Common Rule made in 2017, offering up-to-date recommendations on starting the process with the sharing of essential clinical trial information in ways that patients can understand.

SAMHSA Releases Annual National Survey on Drug Use and Health

SAMHSA released the results of the 2023 National Survey on Drug Use and Health (NSDUH), which shows how people living in the United States reported their experience with mental health conditions, substance use and pursuit of treatment.

Addition of IVIG May Be Superior to Addition of Plasmapheresis in Corticosteroid-Resistant Optic Neuritis: Systemic Review

A meta-analysis and systematic review compared the efficacy of corticosteroids (CS) alone against CS combined with intravenous immune globulin (IVIG) or CS combined with plasmapheresis (PP) in patients with steroid-resistant optic neuritis.

Investigational Plasma Kallikrein Inhibitor (Sebetralstat) Reduces Time to Relief from Hereditary Angioedema Attacks

In a Phase III, double-blind, three-way crossover trial, sebetralstat given on-demand for treatment of hereditary angioedema (HAE) attacks was shown to result in faster times to the start of symptom relief, reduction in attack severity and complete attack resolution than placebo treatment.

Scientists Develop $25 Nasal Spray That Is 99% Effective Against Colds, Flu and COVID-19

profi spray

Scientists at Harvard Medical School have developed a simple nasal spray, made of harmless ingredients, that can protect people against flu, colds and COVID-19 with near-100 percent success, and it costs just $25.

FDA Approves Dupixent for Chronic Obstructive Pulmonary Disease

The U.S. Food and Drug Administration (FDA) has expanded its approval of Dupixent to chronic obstructive pulmonary disease (COPD).

First Nasal Self-Administered Flu Vaccine Approved by FDA

The first influenza nasal spray vaccine that can be self-administered has been approved by the U.S. Food and Drug Administration (FDA).

CDC Identifies New COVID Strain Known as XEC

A newly discovered COVID strain known as XEC continues to spread rapidly across multiple countries, including the U.S.

Lab Value Predictive of COVID-19 Disease Severity in Children

HHS Issues Amendment to PREP Act for Medical Countermeasures Against COVID-19

A study has found measurements of C-reactive protein (CRP), lactate dehydrogenase (LDH) and albumin are potentially predictive markers for disease severity in children hospitalized with COVID-19. 

← Previous
Next →
BioSupply Trends Quarterly logo
FFF Enterprises logo
  • Current Issue
  • Past Issues
  • Resources
  • Current Issue
  • Past Issues
  • Resources
  • About BSTQ
  • Subscribe to BSTQ
  • eNewsletter Opt-in
  • Contact Us
  • About BSTQ
  • Subscribe to BSTQ
  • eNewsletter Opt-in
  • Contact Us
  • Advertiser Information
  • Media Kit
  • Editorial Calendar
  • Editorial Guidelines
  • Advertiser Information
  • Media Kit
  • Editorial Calendar
  • Editorial Guidelines
Facebook-f Instagram Linkedin-in Youtube

FFF Enterprises.com | Privacy Statement | Terms of Use | California Consumer Privacy Act (CCPA) Opt-Out Icon

FFF Enterprises.com
Privacy Statement
Terms of Use
California Consumer Privacy Act (CCPA) Opt-Out Icon

©2024 FFF Enterprises, Inc. All Rights Reserved. Property of FFF Enterprises, Inc.

The information provided on this website is not medical advice, nor is it intended to be a substitute for medical advice, diagnosis, and treatment. Always seek the advice of a physician or other qualified health provider with questions concerning a medical condition. Never disregard professional medical advice, or delay seeking it based on information provided on this website.